Aldeyra Therapeutics intends to formally challenge the FDA’s March 2026 rejection of reproxalap for dry eye disease, with a Formal Dispute Resolution Request and meeting with the agency’s Office of New Drugs expected in the fourth quarter of 2026.
Key Investor Takeaways
- Aldeyra Therapeutics (NASDAQ:ALDX) plans to submit a Formal Dispute Resolution Request seeking to appeal the FDA’s March 16, 2026 Complete Response Letter for reproxalap.
- The latest Complete Response Letter did not request another clinical trial but said the totality of completed trial evidence did not support the drug’s effectiveness.
- Reproxalap has now received three Complete Response Letters following the original NDA and two subsequent resubmissions.
- Aldeyra expects to submit the FDRR and meet with the FDA’s Office of New Drugs during Q4 2026, creating a defined regulatory milestone for the program.
- The company also extended its expected operational cash runway into 2029, based on $45.1 million in cash and cash equivalents as of June 30, 2026.
Why ALDX Stock Is in Focus
Aldeyra is escalating its regulatory effort for reproxalap by moving beyond discussions with the FDA’s Division of Ophthalmology and seeking formal review through the agency’s dispute resolution process.
The planned FDRR will appeal the March 16 Complete Response Letter that denied approval of reproxalap’s New Drug Application for dry eye disease. Aldeyra expects the request to be reviewed by the FDA’s Office of New Drugs.
The decision follows recent Type A and Type D meetings with the Division of Ophthalmology and Office of Specialty Medicine.
The regulatory history remains central to the investment case. Aldeyra has received three Complete Response Letters covering its original NDA and two resubmissions.
The first two letters recommended an additional clinical trial to demonstrate a positive effect on ocular symptoms. The latest letter did not request another study but concluded that the totality of evidence from completed trials did not support reproxalap’s effectiveness.
Aldeyra said it has submitted data from nine adequate and well-controlled trials over the course of the three applications, five of which met all multiplicity-controlled primary endpoints.
Why This Matters for Investors
The Formal Dispute Resolution Request creates a new regulatory pathway for reproxalap after repeated FDA rejections, but it also leaves the program dependent on whether a higher level within the agency reaches a different conclusion about the existing evidence.
Importantly, the latest Complete Response Letter did not explicitly require another clinical trial. That shifts the immediate focus away from generating an additional study and toward the FDA’s interpretation of the clinical evidence already submitted.
The outcome nevertheless remains uncertain. Aldeyra said the timing of an OND decision could depend on requests for additional information, consultation with internal or external experts, or the potential convening of an advisory panel.
CEO Todd Brady said the company is optimistic about the dispute resolution process, citing reproxalap’s activity across multiple clinical trial designs. That represents management’s assessment rather than an indication of how the FDA will decide the appeal.
Aldeyra’s updated cash position provides additional financial flexibility while the regulatory process continues. Based on $45.1 million in cash and cash equivalents at June 30, the company now expects its operational runway to extend into 2029.
What to Watch Next
Submission of the Formal Dispute Resolution Request and the expected Q4 meeting with the Office of New Drugs are the next regulatory milestones.
The subsequent OND response will be particularly important because it could clarify whether the existing reproxalap clinical package can support another path toward approval or whether further regulatory or clinical work will be required.
Investors can also watch for any FDA request for additional information, involvement of outside experts or an advisory panel, all of which could affect the timing and direction of the dispute resolution process.